

## **Covalent-111 Menin inhibition in T2D A Clinical phase II RCT in Type 2 diabetes duration <7 yrs aged 18-65**

**Study location** [BCDiabetes: 400 - 210 West Broadway, Vancouver V5Y 3W2](#)

**Principal Investigators** Dr. Tom Elliott

**Study coordinator & primary contact** [Alireza Moshiri, MD](#) P: 604-628-7253 x 7011 :

### Inclusion & Exclusion criteria

1. Males or females, age  $\geq 18$  and  $\leq 65$  years.
2. Diagnosed with T2D within the last 7 years.
3. Treated with lifestyle management with or without up to 3 antidiabetic medications (metformin\*, sodium-glucose cotransporter 2 [SGLT2] inhibitor, glucagon-like peptide receptor agonists [GLP-1RA], dipeptidyl peptidase-IV inhibitor [DPP4i] [alogliptin and sitagliptin only]) with a stable dose for at least 2 months prior to screening. [No more than 25% of T2D subjects can receive anti-diabetic agents (GLP-1R agonists, SGLT2 inhibitors etc.) other than metformin monotherapy. At least 75% of subjects must be treated with lifestyle management with or without metformin]

*\* If on metformin, the subject must be on a minimum stable dose of  $\geq 500$ mg/day prior to the screening visit.*

4. HbA1c  $\geq 7.0\%$  and  $\leq 10.5\%$  at screening (no more than 25% below 7.5%).
5. BMI  $\geq 25$  and  $\leq 40$ kg/m<sup>2</sup>.
6. If treated with lipid-lowering therapy, the dose must be stable for at least 30 days prior to screening.

**Summary:** BMF-219 is a phase II study of the safety & effectiveness of the menin inhibitor BMF-219 (drug:placebo ratio of 3:1) in Type 2 diabetes aged 18-65 years duration < 7 years. Subjects will receive BMF-219 or placebo daily, in a dose of 100 to 400 mg daily, for a total of 12 weeks over the course of 26 weeks

### **Hypothesis:**

BMF-219 is safe and lowers sugar and A1c by improving insulin secretion.

**Odds of receiving placebo 1/4 (25%)**

### **Study documents:**

[Protocol](#) [Consent form](#) [Ethics Approval](#)

### **Other documents:**

[Conflict of Interest statement](#)

[The science behind menin-inhibition and beta cell regeneration - 5 minute video](#)

[Why BMF-219 menin inhibition is unlike the zero menin state of MEN1 syndrome \(3 minute video\)](#)

Short URL to this document: <https://bit.ly/BiomeaT2>